IDNAvsETF 2ETF Comparison
VS
ETF 2
Choose a second ETF to run a side-by-side ETF comparison with IDNA, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
IDNA performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/10/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | IDNA ETF 2 | +7.41%– | +33.01%– | +45.04%– | +69.35%– | +75.19%– | -27.47%– |
| Flows | IDNA ETF 2 | +$29M– | +$43M– | +$58M– | +$58M– | +$37M– | +$28M– |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | IDNA ETF 2 | +37.14%– | +27.93%– | +25.61%– | +28.64%– |
| Max drawdown | IDNA ETF 2 | -8.56%– | -10.60%– | -29.33%– | -68.19%– |
| Max drawdown duration | IDNA ETF 2 | 16d– | 46d– | 347d– | 1817d– |
Trading data
IDNA | ETF 2 | |
Last sale 9/11/2026 at 1:30 PM | $38.06 | – |
| Previous close 09/10/2026 | $37.88 | – |
| Consolidated volume 09/10/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
IDNA | ETF 2 | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/11/2026 at 1:30 PM
Live
Closed
IDNA | ETF 2 | |
|---|---|---|
| Last price | $38.06 | – |
| 1D performance | +0.48% | – |
| AuM | $251.49 M | – |
| E/R | 0.47% | – |
Characteristics
IDNA | ETF 2 | |
|---|---|---|
| Management strategy | Passive | – |
| Provider | iShares | – |
| Benchmark | NYSE FactSet Global Genomics and Immuno Biopharma Index | – |
| N° of holdings | 48 | – |
| Asset class | Equities | – |
| Trailing 12m distribution yield | Join | Join |
| Inception date | June 11, 2019 | – |
| ESG | No | – |
Advertisement
Exposure
Countries
IDNA
USA
60.45%
Germany
8.54%
France
7.32%
Other
23.69%
ETF 2
Sectors
IDNA
Healthcare
99.74%
Other
0.26%
ETF 2
Advertisement
Diversification
IDNA
Total weight of top 15 holdings out of 15
61.45%
ETF 2
–
Top 15 holdings
Data as of July 31, 2026
IDNA
Bayer AG
4.77%
Twist Bioscience Corp.
4.72%
Revolution Medicines, Inc.
4.61%
Moderna, Inc.
4.37%
Incyte Corp.
4.30%
Takeda Pharmaceutical Co., Ltd.
4.18%
Regeneron Pharmaceuticals, Inc.
4.16%
Genmab A/S
4.12%
Vertex Pharmaceuticals, Inc.
3.86%
Merck & Co., Inc.
3.85%
Roche Holding AG
3.80%
Exelixis, Inc.
3.80%
BioNTech SE
3.77%
GSK Plc
3.59%
Ipsen SA
3.55%
ETF 2
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Advertisement
Advertisement
